Matrix-degrading enzymes tissue plasminogen activator and matrix metalloprotease-3 in the hypothalamo-neurohypophysial system.
The hypothalamo-neurohypophysial system (HNS), synthesizing arginine vasopressin (AVP) and oxytocin (OXT), is well known to show structural plasticity during chronic physiological stimulation such as salt loading and lactation. In the present study, we undertook in the HNS to study localization and activity-dependent changes in the expression of matrix-degrading enzymes such as tissue plasminogen activator (tPA) and matrix metalloprotease-3 (MMP-3). Double labeling confocal microscopy demonstrated that the immunoreactivity of tPA was localized at AVP-positive dendrites in the supraoptic nucleus (SON) and AVP-positive terminals in the neurohypophysis (NH). The immunoreactivity of tPA was also seen at astrocytic processes in the HNS. Likewise, the immunoreactivity of MMP-3 was observed at AVP-positive dendrites and terminals. High magnification observation further revealed punctate distribution of tPA and MMP-3 immunoreactivity at dendrites and terminals, suggesting that they are localized at neurosecretory granules. Salt loading, known as the chronic stimulation to cause the structural plasticity, increased protein and mRNA levels of tPA in the SON but reduced protein levels of it in the NH. The chronic stimulation also increased protein levels of urokinase plasminogen activator in the SON, but the stimulation did not change protein levels of MMP-3 in the SON and NH. Depolarizing agent KCl released tPA from isolated neurosecretosomes, and this depolarization-dependent release was abolished by verapamil, a Ca(2+) channel blocker. These results demonstrate that tPA and MMP-3 are localized mainly at dendrites and terminals of AVP-expressing magnocellular neurons and tPA is released in an activity-dependent manner, suggesting that matrix-degrading proteases are candidate molecules to be concerned with the structural plasticity in the HNS.
Miyata
Seiji
S
Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki, Kyoto, Japan. smiyata@kit.ac.jp
Nakatani
Yoshihiro
Y
Hayashi
Noriko
N
Nakashima
Toshihiro
T
D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D003712:Dendrites / Q000201:enzymology / Q000648:ultrastructure; D007030:Hypothalamo-Hypophyseal System / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000378:metabolism*; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D018613:Microscopy, Confocal; D009473:Neuronal Plasticity / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D010904:Pituitary Gland, Posterior / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D011189:Potassium Chloride / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000201:enzymology / Q000648:ultrastructure; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D022142:Secretory Vesicles / Q000378:metabolism / Q000648:ultrastructure; D013495:Supraoptic Nucleus / Q000166:cytology / Q000201:enzymology; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation / Q000502:physiology; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D012333:RNA, Messenger; D001127:Arginine Vasopressin; D011189:Potassium Chloride; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D019278:Matrix Metalloproteinase 3